ATELVIA Drug Patent Profile

When do Atelvia patents expire, and when can generic versions of Atelvia launch?

Atelvia is a drug marketed by Apil and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-five patent family members in thirty-three countries.

The generic ingredient in ATELVIA is risedronate sodium. There are nineteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Atelvia

A generic version of ATELVIA was approved as risedronate sodium by TEVA PHARMS USA on October 5^th, 2007.

Summary for ATELVIA

International Patents:	85
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	70
Clinical Trials:	2
Patent Applications:	2,880
Drug Prices:	Drug price information for ATELVIA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ATELVIA
What excipients (inactive ingredients) are in ATELVIA?	ATELVIA excipients list
DailyMed Link:	ATELVIA at DailyMed

See drug prices for ATELVIA

See drug sales revenues for ATELVIA

Recent Clinical Trials for ATELVIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 3
National Cancer Institute (NCI)	Phase 2
Wake Forest University Health Sciences	Phase 2

See all ATELVIA clinical trials

Pharmacology for ATELVIA

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for ATELVIA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ATELVIA	Delayed-release Tablets	risedronate sodium	35 mg	022560	1	2011-06-09

US Patents and Regulatory Information for ATELVIA

ATELVIA is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	AB	RX	Yes	Yes	7,645,460		Y
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	AB	RX	Yes	Yes	7,645,459		Y
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	AB	RX	Yes	Yes	8,246,989		Y

Expired US Patents for ATELVIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	5,622,721
Apil	ATELVIA	risedronate sodium	TABLET, DELAYED RELEASE;ORAL	022560-001	Oct 8, 2010	8,246,989

International Patents for ATELVIA

See the table below for patents covering ATELVIA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	61370
Australia	5153485
Australia	587001
Canada	1320727	COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DIPHOSPHONATES GEMINAUX (PHARMACEUTICAL COMPOSITIONS CONTAINING GEMINAL DIPHOSPHONATES)
Germany	10075030
Germany	3582033
Denmark	168754

Supplementary Protection Certificates for ATELVIA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0186405	SPC/GB00/021	United Kingdom		PRODUCT NAME: (1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE)BIS(PHOSPHONIC ACID) "RESIDRONATE" AND SALTS THEREOF, ESPECIALLY THE SODIUM SALT; REGISTERED: SE 15296 19991007; SE 15297 19991007; UK PL 00364/0070 20000316
0186405	C300031	Netherlands		PRODUCT NAME: RISEDRONINEZUUR, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF FARMACEUTISCH AANVAARDBARE ESTER, IN HET BIJZONDER NATRIUMRISEDRONAAT; NAT REGISTRATION NO/DATE: RVG 24990 20000609; FIRST REGISTRATION: SE 15290 - 15297 19991007
0186405	2000C/028	Belgium		PRODUCT NAME: NATRIUMRISEDRONAAT; NAT. REGISTRATION NO/DATE: 354 IS 498 F3 20000508; FIRST REGISTRATION: SE 15290 19991007

Last updated: July 29, 2026

Atelvia (risedronate) Market Dynamics and Financial Trajectory: Demand drivers, pricing pressure, exclusivity cliffs, and generic entry risk

Atelvia’s U.S. sales trajectory is defined by (1) a mature branded bisphosphonate category, (2) steady pricing compression after first generic exposure of risedronate products, and (3) an exclusivity and patent estate that is now in the late-life stage for the specific Atelvia regimen (delayed-release risedronate tablet). In practice, Atelvia functions like a legacy brand competing against multiple oral risedronate options and generic pressures, with margin and revenue increasingly tied to payer formulary placement and channel dynamics rather than uptake expansion.

Because “Atelvia” is a brand for risedronate and multiple risedronate formulations exist, forecasting outcomes depends on (a) which risedronate dosage forms are on formulary and (b) whether plan designs treat Atelvia as substitutable within the risedronate class.

---

What is Atelvia’s product profile and how does that shape market demand?

Atelvia is an oral risedronate product in a delayed-release formulation designed for dosing flexibility versus standard regimens. Commercial demand is driven by:

• Osteoporosis prevalence and treatment adherence in U.S. ambulatory care
• Prescriber switching behavior within bisphosphonates based on perceived GI tolerability and dosing convenience
• Payer restriction patterns: tier placement, prior authorization, and step edits against alternative generic bisphosphonates
• Competing class therapies (notably denosumab and anabolic agents) that cap market growth for oral bisphosphonates

Featured snippet answer: Atelvia demand is largely substitution-driven. Growth is limited because risedronate is a mature molecule with multiple generic and class alternatives; Atelvia’s differentiator is delayed-release dosing convenience, which affects prescribing and payer coverage rather than creating sustained market expansion.

---

How do payer formularies typically treat Atelvia versus other osteoporosis drugs?

• Generic risedronate products usually receive preferential tier placement, reducing branded share.
• Non-bisphosphonate osteoporosis therapies (denosumab, teriparatide/abaloparatide, romosozumab) often win formulary slots in patients who fail or cannot tolerate oral therapy, shifting patient mix away from Atelvia.

---

What patient segments drive Atelvia prescribing?

• Patients initiating oral therapy who require or prefer a regimen perceived to improve GI tolerability
• Patients already on a risedronate pathway and staying with the current agent to avoid switching
• Clinicians aiming to reduce complexity versus older dosing instructions

---

How strong is Atelvia’s patent estate and when does it lose exclusivity?

Atelvia’s market economics are governed by late-stage branded life-cycle conditions: key composition-of-matter exclusivity for risedronate products is long expired for the underlying active ingredient, leaving value centered on formulation-specific and method-of-use protections that historically would protect the delayed-release regimen or specific dosing instructions.

Featured snippet answer: Atelvia’s ability to defend price is limited to formulation/method patents that have largely moved into expiration or near-expiration territory, so the practical exclusivity barrier today is weaker than it would be early in product life.

---

What patent categories have mattered historically for Atelvia?

• Formulation and delayed-release technology
• Dosing instructions and patient use timing (method-of-use angles)
• Manufacturing process and stability-related claims

---

When does generic entry typically occur for late-life branded risedronate products?

• Generics usually enter when Orange Book-listed exclusivities and patent barriers fall away or are successfully challenged via Paragraph IV with a settlement that permits launch dates.
• For late-life products, generic entry often follows a narrow window where any remaining patent exclusivity is not enough to deter ANDA filings.

---

What is the Orange Book status of Atelvia and how many patents are listed?

Orange Book status is the operational determinant of FDA and litigation timing for any ANDA.

Featured snippet answer: Atelvia’s Orange Book listing is the checkpoint for generic launch risk. When relevant Orange Book patents expire or lose enforceability, ANDA approvals become commercially decisive.

---

What to look for in Atelvia’s Orange Book listing

• Number of Orange Book patents linked to the listed NDA
• Remaining patent expiration dates
• Any exclusivity codes (for example, new chemical entity exclusivity is typically irrelevant for risedronate itself given its age; formulation or method exclusivity is the relevant risk driver)

(At this stage of the request, no Orange Book list contents or dates are provided in the prompt; producing a complete patent-count and expiration table would require the specific NDA identifier and the Orange Book record contents.)

---

How does Atelvia compare with generics and other osteoporosis drugs on the competitive field?

Atelvia competes on:

• Oral bisphosphonate class substitution
• Dosing convenience versus strict older bisphosphonate instructions
• Formulary placement and copay strategy

Atelvia loses on:

• Price versus generic oral risedronate
• Patient share versus injectable or alternative mechanisms in formulary environments

---

Atelvia versus other risedronate options: what matters to the payer

• If payer formularies treat oral risedronate as interchangeable, Atelvia becomes a brand with limited defensibility.
• If delayed-release dosing is treated as a preferred option for adherence or tolerability, Atelvia can hold share longer.

---

Atelvia versus denosumab and anabolic therapies

• Injectable mechanisms shift patient selection in later lines of care.
• Oral bisphosphonates, including risedronate, face declining incremental growth where injectables are favored due to adherence outcomes or guideline preferences for specific risk groups.

---

What generic entry risks exist for Atelvia and what would drive a rapid share loss?

Share loss risk typically accelerates when three conditions align:

1. Orange Book barriers clear (patents/exclusivity expire or are invalidated)
2. ANDA entrants launch at aggressive net pricing
3. Payers update formularies to route patients to lower-cost alternatives

Featured snippet answer: The highest generic-entry risk scenario is “barrier clearance plus immediate payer switching.” Once switching occurs, Atelvia revenue can compress quickly due to wholesale-to-retail margin reallocation and tier migration.

---

What settlement patterns usually affect Atelvia-style late-life launches?

• Atelvia could have experienced settlements that permitted generic launch at an agreed date after patent litigation.
• These settlements typically protect a brand’s final-year net revenue by limiting early generic exposure, then end the defense window quickly once launch is allowed.

(Without specific Paragraph IV case identifiers, settlement dates, or NDA/patent numbers, a litigation-accurate timeline cannot be generated.)

---

What litigation and FDA pathway events affect Atelvia’s commercialization?

For branded osteoporosis drugs in late life, litigation generally clusters around:

• ANDA filings citing non-infringement or invalidity
• Settlement agreements delaying launches
• Post-launch disputes about label carve-outs or switching triggers

Featured snippet answer: Litigation matters most when it delays first generic approval and launch. After multiple generics exist, litigation impact on overall sales tends to diminish unless an entrant brings a disruptive pricing strategy.

---

What to track for Atelvia going forward

• New FDA approvals for risedronate generics tied to the same dosing form
• Label changes that alter interchangeability or patient selection
• Any further Orange Book disputes that affect launch timing

---

How has Atelvia’s financial trajectory looked versus category peers?

Financial trajectory drivers for Atelvia:

• Branded revenue decline driven by generic substitution
• Net price erosion from payer negotiations and rebate pressure
• Mix shift from new scripts to remaining maintenance patients
• Residual demand influenced by tolerability perception and prescriber habit

Featured snippet answer: For late-life branded risedronate, the standard financial arc is steepening revenue decline as generic penetration rises and payer tier management strengthens. Upside is limited unless delayed-release convenience creates formulary “preference” behavior.

---

Where financial performance tends to diverge within oral osteoporosis

• Brands that retain a “preferred” tier for GI tolerability can hold revenue longer
• Brands that are treated as interchangeable often face faster price compression
• Products that align to adherence initiatives can preserve volume marginally longer

(Actual Atelvia revenue figures, quarter-by-quarter, are not provided in the prompt; including numeric revenues would require a primary financial statement dataset or investor disclosures.)

---

What KPIs map to Atelvia sales performance

• Net sales and gross-to-net trend (rebates, discounts)
• Prescription volume trends for risedronate delayed-release versus generic risedronate tablets
• Wholesaler channel inventory dynamics
• Formulary status by payer segment

---

What commercial levers can extend Atelvia profitability despite generic pressure?

Payer and market tactics that can slow revenue erosion:

• Contracting and rebate structures to maintain preferred status
• Targeted stewardship programs with payers and pharmacy benefit managers
• Segment focus on patients who have tolerated the delayed-release regimen
• Restrictive step therapy programs that do not fully concede interchangeability

Featured snippet answer: Profitability extension depends on keeping Atelvia on payer preferred tiers and limiting rapid switching immediately after generic entry.

---

Key Takeaways

• Atelvia’s market is shaped by mature risedronate substitution dynamics and oral bisphosphonate competitive pressure.
• Revenue trajectory is typically a late-life decline driven by generic pricing and payer tier migration.
• The operational determinants of future share loss are Orange Book barrier clearance (patents/exclusivity) and payer switching behavior, not incremental demand growth.
• Profitability can be extended only if Atelvia retains formulary preference or patient switching inertia after generic launch.

---

FAQs

1. What makes Atelvia different from other risedronate tablets on formulary?
   Delayed-release dosing convenience can influence prescriber preference and payer coverage decisions when treated as less GI-disruptive or easier to maintain.

2. Do biosimilars affect Atelvia’s market dynamics?
   Biosimilars mainly affect biologic osteoporosis competitors (e.g., denosumab-related pathways indirectly depending on approvals), not risedronate directly.

3. How does payer step therapy typically impact Atelvia adoption?
   Step edits and prior authorization against lower-cost oral bisphosphonates usually reduce initiation volume and drive substitution from Atelvia.

4. What is the most important timing driver for generic risk in Atelvia?
   Orange Book patent expiration dates and any remaining exclusivity linked to the specific NDA product prevent or delay ANDA launches.

5. Is Atelvia vulnerable to accelerated volume loss after generic launch?
   Yes, when launch coincides with payer formulary updates that move patients to generic risedronate quickly.

---

References

1. FDA Orange Book: Therapeutic Equivalence Evaluations (Drug Products). U.S. Food and Drug Administration.
2. FDA Drug Approval Reports and Labeling for Atelvia (risedronate). U.S. Food and Drug Administration.
3. Formulary and pricing frameworks in U.S. outpatient pharmaceuticals (PBM and insurer contracting dynamics).